By Erin Marie Daly (May 20, 2008, 12:00 AM EDT) -- Wyeth Pharmaceuticals Inc. and Nycomed GmbH have moved again to protect a patent for their injectable heartburn treatment Protonix, launching a lawsuit against a unit of Novartis AG that plans a copycat version of the drug.
The suit, filed Friday in the U.S. District Court for the Northern District of Illinois, seeks a court order that Novartis' generics-making subsidiary, Sandoz Inc., infringed a patent covering Protonix IV, marketed by Wyeth, which licenses the patent from Nycomed.
According to the complaint, Sandoz notified the Madison, N.J.-based Wyeth and Germany's Nycomed in April that it had filed an abbreviated new drug application with...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!